Video
Dr. Susanibar-Adaniya on the Impact of the MAIA and GRIFFIN Trials in Multiple Myeloma Treatment
Author(s):
Sandra P. Susanibar-Adaniya, MD, discusses 2 key trials in multiple myeloma that improved the treatment landscape for transplant-eligible and ineligible patients.
Sandra P. Susanibar-Adaniya, MD, assistant professor of medicine, Penn Medicine,University of Pennsylvania, discusses 2 key trials in multiple myeloma that improved the treatment landscape for transplant-eligible and ineligible patients.
The phase 3 MAIA study (NCT02252172) evaluated the addition of daratumumab (Darzalex) to the previous standard-of-care doublet of lenalidomide (Revlimid) plus dexamethasone (DRd).
The introduction of the triplet regimen, DRd, has improved the treatment paradigm for transplant-ineligible patients, Susanibar-Adaniya states. However, the lack of head-to-head comparisons trials with modified bortezomib (Velcade), lenalidomide, and dexamethasone (RVd) makes it difficult to determine which regimen is superior, Susanibar-Adaniya explains. The use of either regimen as a first-line treatment option can be beneficial, Susanibar-Adaniya says.
Moreover, the phase 2 GRIFFIN trial (NCT02874742) compares daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd) with RVd, Susanibar-Adaniya continues. The trial showed promising results with D-RVd for transplant-eligible patients with newly diagnosed multiple myeloma, Susanibar-Adaniya adds.
Future phase 3 studies aim to confirm these clinical benefits in larger patient populations and understand the benefits associated with these respective regimens, Susanibar-Adaniya concludes.
